No evidence of JC virus reactivation in natalizumab treated multiple sclerosis patients: an 18 month follow-up study

2010 ◽  
Vol 81 (12) ◽  
pp. 1345-1350 ◽  
Author(s):  
L. Rinaldi ◽  
F. Rinaldi ◽  
P. Perini ◽  
M. Calabrese ◽  
D. Seppi ◽  
...  
2014 ◽  
Vol 85 (10) ◽  
pp. 1109-1115 ◽  
Author(s):  
Cecilie Jacobsen ◽  
Jesper Hagemeier ◽  
Kjell-Morten Myhr ◽  
Harald Nyland ◽  
Kirsten Lode ◽  
...  

2007 ◽  
Vol 13 (8) ◽  
pp. 1068-1070 ◽  
Author(s):  
L. Roccatagliata ◽  
MA Rocca ◽  
P. Valsasina ◽  
L. Bonzano ◽  
MP Sormani ◽  
...  

Using MRI, we measured disease activity and brain atrophy in nine multiple sclerosis patients treated with autologous hematopoietic stem cell transplantation (AHSCT) for a mean follow up of 63 months. We show that AHSCT is associated to a longlasting suppression of inflammation and to a marked decrease of the rate of brain atrophy after the second year following treatment. Multiple Sclerosis 2007; 13 : 1068—1070. http://msj.sagepub.com


2006 ◽  
Vol 245 (1-2) ◽  
pp. 77-85 ◽  
Author(s):  
Agnete Jønsson ◽  
Jente Andresen ◽  
Lars Storr ◽  
Thomas Tscherning ◽  
Per Soelberg Sørensen ◽  
...  

2015 ◽  
Vol 357 (1-2) ◽  
pp. 106-108 ◽  
Author(s):  
Giannina Arru ◽  
Elisa Caggiu ◽  
Stefania Leoni ◽  
Giuseppe Mameli ◽  
Maura Pugliatti ◽  
...  

2007 ◽  
Vol 13 (5) ◽  
pp. 590-595 ◽  
Author(s):  
Roberto Alvarez-Lafuente ◽  
Marta García-Montojo ◽  
Virginia De Las Heras ◽  
Manuel Bartolomé ◽  
Rafael Arroyo

Objective To evaluate the possible involvement of JC virus (JCV) in the aetiology of multiple sclerosis (MS), through the comparison of DNA prevalences and viral loads of JCV in cerebrospinal fluid (CSF) of MS patients at the first demyelinating event and subjects suffering from other neurological diseases (OND). Methods Seventy-three CSF samples (43 from MS patients at the first demyelinating event, and 30 from patients with OND) were collected; all MS cases were followed up from 1 to 6.7 years after they were diagnosed with clinically definite MS. DNA was extracted and analysed by real-time PCR for the detection of JCV genomes. Results We found JCV DNA in the CSF of two MS patients (4.7%) with a mean viral load of 2.1 and 6.7 copies/mL of CSF. Among the patients of the OND group we did not find any positive sample. We did not find any difference in the course of the disease between MS patients with and without JCV genomes in their CSF along the follow up. Conclusion JCV seems to be only a bystander in the pathology of MS, and the presence of cell-free viral particles could be related to the immunological activation of the disease, mainly during relapses. Multiple Sclerosis 2007; 13: 590-595. http://msj.sagepub.com


2000 ◽  
Vol 6 (6) ◽  
pp. 373-377 ◽  
Author(s):  
E. Fisher ◽  
R.A. Rudick ◽  
G. Cutter ◽  
M. Baier ◽  
D. Miller ◽  
...  

2015 ◽  
Vol 359 (1-2) ◽  
pp. 323-327 ◽  
Author(s):  
Fumihito Yoshii ◽  
Shigeharu Takagi ◽  
Eiichiro Nagata ◽  
Yasuhiro Hasegawa ◽  
Naoya Kunika ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document